Catalent, Inc.: management transactions · United States · SEC (Form 4)

About Catalent, Inc.

Catalent, Inc. is a leading contract development and manufacturing organization (CDMO) serving pharmaceutical, biotech, and consumer health customers. The company is US-listed on the NYSE/NASDAQ market in the United States (United States), and its investment profile sits squarely in the healthcare outsourcing value chain. Catalent traces its roots to 2007, when it was formed from assets formerly part of Cardinal Health’s pharmaceutical technologies and services platform, and it has since been shaped by a long series of acquisitions and capacity investments. Historically, the company built capabilities around drug-delivery innovation, including softgel technologies, fast-dissolve dosage forms, and cell-line development platforms, giving it a broader technology base than a conventional toll manufacturer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1416083/000141608313000014/catalent-20130630x10k.htm?utm_source=openai)) Operationally, Catalent offers integrated services across product development, fill-finish, multi-modal manufacturing, packaging, and supply-chain support. The company describes itself as a partner that helps customers move programs from early development through launch and lifecycle supply, and it has stated that its teams support more than 100 new product launches each year while working on about 1,500 active customer development programs. Its capabilities span small molecules, oral solids, injectables, biologics, consumer health products, and more specialized platforms such as antibody-drug conjugates and cell therapies. This breadth matters strategically because it allows Catalent to capture work earlier in the product lifecycle and deepen customer relationships over time. ([catalent.com](https://www.catalent.com/about-us/overview/?utm_source=openai)) Catalent’s geographic footprint is global, with nearly 40 sites and a presence across North America, Europe, and other key life-sciences markets. In 2025, the company opened a new global corporate headquarters in Tampa, Florida, while maintaining a significant manufacturing presence in nearby St. Petersburg and a long-standing operational base in New Jersey. That mix of headquarters and manufacturing locations reflects Catalent’s effort to align corporate functions with industrial execution and customer support in major life-sciences hubs. ([catalent.com](https://www.catalent.com/about-us/overview/?utm_source=openai)) From a competitive standpoint, Catalent is positioned as a scaled, science-led CDMO with meaningful barriers to entry created by regulatory expertise, quality systems, technical know-how, and manufacturing complexity. Compared with narrower outsourcing peers, Catalent’s differentiation comes from its ability to combine formulation, development, and commercial supply under one roof, which can be attractive for pharma and biotech clients seeking speed, reliability, and flexible capacity. Recent developments have also been material from a corporate perspective. Novo Holdings completed its all-cash acquisition of Catalent in 2024 in a transaction with an enterprise value of approximately $16.5 billion, materially changing the company’s ownership structure and strategic backdrop. In 2025 and 2026, Catalent announced a new corporate headquarters, a refreshed brand, and new partnership and licensing activities, reinforcing a narrative centered on innovation, customer service, and lifecycle partnership. ([catalent.com](https://www.catalent.com/catalent-news/novo-holdings-completes-acquisition-of-catalent/?utm_source=openai))